CG
KALV

Cutler Group’s KalVista Pharmaceuticals KALV Stock Holding History

Cutler Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,600
Closed -$4K – 6029
2021
Q1 		$4K Buy
1,600
+500
+45% +$13.1K ﹤0.01% 4521
2020
Q4 		$8K Buy
+1,100
New +$18.9K ﹤0.01% 3348

Other funds holding KALV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cutler Group's KALV Position: Q4 2021 in Review

Cutler Group sold out of KalVista Pharmaceuticals (KALV) in Q4 2021, closing a stake of 100 shares — an estimated $1K sold.

Cutler Group first reported a position in KALV in Q4 2020 and held it in 2 quarters. The position peaked at $13K in Q4 2020. 97 funds tracked by Wall St. Rank hold KALV as of Q4 2021.

  • Cutler Group reported no remaining KalVista Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Cutler Group sold 100 KalVista Pharmaceuticals shares in Q4 2021, an estimated $1K.
  • Cutler Group first reported a position in KalVista Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Cutler Group's KalVista Pharmaceuticals position peaked at $13K in Q4 2020.
  • 97 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.